Citigroup Inc Graphite Bio, Inc. Transaction History

Citigroup Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.24 - $2.66 $7,448 - $8,844	3,325 Added 453.62%	4,058 $10,000
Q3 2023 Nov 09, 2023	SELL	$2.18 - $2.77 $18,741 - $23,813	-8,597 Reduced 92.14%	733 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.47 - $3.38 $21,407 - $29,294	8,667 Added 1307.24%	9,330 $24,000
Q1 2023 May 11, 2023	SELL	$1.85 - $3.21 $130,410 - $226,279	-70,492 Reduced 99.07%	663 $1,000
Q4 2022 Feb 09, 2023	BUY	$2.82 - $3.59 $198,409 - $252,585	70,358 Added 8827.85%	71,155 $236,000
Q3 2022 Nov 10, 2022	SELL	$2.82 - $4.24 $9,695 - $14,577	-3,438 Reduced 81.18%	797 $3,000
Q2 2022 Aug 10, 2022	BUY	$2.14 - $5.23 $3,954 - $9,665	1,848 Added 77.42%	4,235 $12,000
Q1 2022 May 12, 2022	SELL	$5.1 - $13.06 $17,416 - $44,599	-3,415 Reduced 58.86%	2,387 $12,000
Q4 2021 Feb 10, 2022	BUY	$8.41 - $16.71 $32,925 - $65,419	3,915 Added 207.47%	5,802 $72,000
Q3 2021 Nov 10, 2021	BUY	$15.81 - $28.39 $29,833 - $53,571	1,887 New	1,887 $31,000

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.